AIP – Atherogenic index of plasma like significant predictor of cardiovascular risk: from research to practice

Česká verzia

Authors: M. Dobiášová
Authors place of work: Fyziologický ústav Akademie věd České republiky, ředitel RNDr. Jaroslav Kuneš, DrSc.
Published in the journal: Vnitř Lék 2006; 52(1): 64-71
Category: Review

Předneseno na Kongresu „Pokroky ve farmakoterapii 2005 pro lékaře v praxi“ ve Zlíně ve dnech 7. - 9. září 2005

Summary

Background:
Various indices have been used for the diagnosis and prognosis of cardiovascular disease (CVD). Atherogenic index of plasma (AIP) is a logarithmically transformed ratio of molar concentrations of triglycerides to HDL-cholesterol. The strong correlation of AIP with lipoprotein particle size may explain its high predictive value. Here we summarize data on AIP calculated in 8394 subjects from 6 population and clinical studies.

Results:
AIP values increase with increasing CV risk. Thus umbilical cord, young children, healthy women have values below 0.1 while men and subjects with CV risk factors such as hypertension, diabetes, dyslipidemia have increasing values up to 0.4. Based on these data we suggest that AIP values of –0.3 to 0.1 are associated with low, 0.1 to 0.24 with medium and above 0.24 with high CV risk. In the population study men had higher AIP values than women. In a cohort undergoing coronary angiography AIP, in model that included age, BMI, waist circumference, type 2. DM, blood pressure, smoking, TG, TC, LDL-C, apoB, HDL-C, and TC/HDL-C, AIP was the best predictor of positive findings. AIP was also a highly sensitive marker of differences of lipoprotein profiles in families of patients with premature myocardial infarction and control families. Treatment with ciprofibrate, and combination of statin and niacin dramatically decreased AIP. Combination with hypoglycemic therapy that included pioglitazone decreased AIP in patiens with type 2. diabetes.

Conclusions:
AIP can be easily calculated from standard lipid profile. As a marker of lipoprotein particle size it adds predictive value beyond that of the individual lipids, and/or TC/HDL-C ratio.

Key words:
lipoprotein particle size – cardiovascular disease – atherogenic Index of Plasma [Log(TG/HDL-C)] – esterification rate of cholesterol in HDL (FER_HDL)

Zdroje

1. Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleteed plasma (FERHDL). Clinical Biochemistry 2001; 34: 583-588.

2. Dobiášová M. Atherogenic index of plasma [Log(triglycerides/HDL/cholesterol]: Theoretical and practical implications. Clin Chem 2004; 50: 113-115.

3. Dobiášová M, Stříbrná J, Sparks DL et al. Cholesterol esterification rates in very low density lipoprotein and low density lipoprotein-depleted plasma: relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arteriosclerosis and Thrombosis 1991; 11: 64-70.

4. Campos H, Genest Jr JJ, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992; 12: 187-195.

5. Coresh J, Kwiterovich PO Jr, Smith HH et al. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993; 34: 1687-1697.

6. Superko RH. Beyond cholesterol reduction. Circulation 1996; 94: 2351-2360.

7. Dobiášová M, Stříbrná J, Pritchard P et al. Cholesterol esterification rate in plasma depleted of very low and low density lipoprotein is controlled by he proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle aged and septuagenarian men. J Lipid Res 1992; 33: 1411-1418.

8. Dobiášová M, Frohlich J. Assays of lecithin cholesterol acyltransferase (LCAT). In: Ordovas JM (ed). Methods in molecular biology. Lipoprotein protocols. Totowa: Humana Press 1998: 217-230.

9. Rainwater DL. Electrophoretic separation of LDL and HDL subclasses In: Ordovas JM (ed). Methods in molecular biology. Lipoprotein protocols. Totowa: Humana Press 1998: 137-151.

10. Freedman DS, Otvos JD, Jeyarajah EJ et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1046-1053.

11. Dobiášová M, Frohlich J. Measurement of fractional esterification rate of cholesterol in apoB containing lipoproteins depleted plasma: methods and normal values. Physiol Res 1996; 45: 65-73.

12. Rašlová K, Nagyová A, Dobiášová M et al. Effect of ciprofibrate on lipoprotein metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype. Acta Diabetol 2000, 37: 131-134.

13. Williams PT, Superko HR, Haskell WL et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003; 23: 314-321.

14. Brown BG, Xue-Qiao Z, Chait A et al. Simvastatin and Niacin, antioxidans vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.

15. Dobiášová M, Frohlich J, Brown BG et al. Relation of FERHDL and AIP to clinical and laboratory parameters in HATS. 75th EAS Congress, Prague, May 2005.

16. Frohlich J, Dobiášová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003; 49: 1873-1880.

17. Tan MH, Johns D, Glazer NB. Pioglitazone Reduces Atherogenic Index of Plasma in Patients with Type 2 Diabetes. Clin Chem 2004; 50: 111-115.

18. Plášková M, Cifková R, Škodová Z et al. A logarithmically transformed ratio of triglyceride/HDL-cholesterol as an indicator of the atherogenic risk in the Czech population. 75th EAS Congress, Prague, May 2005.

19. Dobiášová M, Rašlová K, Rauchová H et al. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction; fractional esterification rate of cholesterol in plasma depleted of apoB lipoproteins (FERHDL) and logarithmically transformed ratio of triglycerides to HDL-cholesterol. Physiol Res 2001, 50: 1-8.

20. Dobiášová M, Frohlich J. Nový aterogenní index plazmy (AIP) odpovídá poměru triglyceridů a HDL-cholesterolu, velikosti částic lipoproteidů a esterifikační rychlosti cholesterolu: změny po léčbě lipanorem. Vnitř Lék 2000; 46: 152-156.